Skip to main content
SpringerLink
Log in

Pemphigus Vulgaris

  • Chapter
  • First Online:
Book cover Autoimmune Bullous Diseases

  • 871 Accesses

Abstract

Pemphigus vulgaris (PV) is an autoimmune mucocutaneous blistering disorder for which early recognition and treatment are necessary to achieve a favourable prognosis. A multidisciplinary, patient-centred approach is required to optimize therapeutic outcomes. Systemic corticosteroids remain first-line treatment for PV patients, yet their optimal dosing regimen remains unknown. Further, various steroid-sparing adjuvants play an important role in the treatment of PV. As clinical trials in the field are limited by small sample sizes and a lack of standardized outcome measures, a therapeutic algorithm is presented to guide the management of PV patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011;29:432–6.

    Article  PubMed  Google Scholar 

  2. Ruocco V, Ruocco E, Lo Schiavo A, Brunetti G, Guerrera LP, Wolf R. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol. 2013;31:374–81.

    Article  PubMed  Google Scholar 

  3. Zaraa I, Sellami A, Bouguerra C, et al. Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study. J Eur Acad Dermatol Venereol. 2011;25:1160–7.

    Article  CAS  PubMed  Google Scholar 

  4. Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med. 1964;117:505–10.

    Google Scholar 

  5. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med. 1982;306:1189–96.

    Article  CAS  PubMed  Google Scholar 

  6. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869–77.

    Article  CAS  PubMed  Google Scholar 

  7. Koch PJ, Mahoney MG, Ishikawa H, et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol. 1997;137:1091–102.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Yamamoto T, Ikeda K, Sasaoka S, et al. Human leukocyte antigen genotypes and antibody profiles associated with familial pemphigus in Japanese. J Dermatol. 2011;38:711–6.

    Article  PubMed  Google Scholar 

  9. Mohan MP, Ramesh TC. Multiple autoimmune syndrome. Indian J Dermatol Venereol Leprol. 2003;69:298–9.

    CAS  PubMed  Google Scholar 

  10. Parameswaran A, Attwood K, Sato R, Seiffert-Sinha K, Sinha AA. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis, and type I diabetes. Br J Dermatol. 2015;172(3):729–38.

    Article  CAS  PubMed  Google Scholar 

  11. Ruocco E, Wolf R, Ruocco V, Brunetti G, Romano F, Lo Schiavo A. Pemphigus: associations and management guidelines: facts and controversies. Clin Dermatol. 2013;31:382–90.

    Article  PubMed  Google Scholar 

  12. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366:61–73.

    Article  PubMed  Google Scholar 

  13. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405–14.

    Article  CAS  PubMed  Google Scholar 

  14. Iraji F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol. 2010;9:684–6.

    PubMed  Google Scholar 

  15. Cohen SN, Lim RP, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol. 2006;45:1379.

    Article  PubMed  Google Scholar 

  16. Tabrizi MN, Chams-Davatchi C, Esmaeeli N, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2007;21:79–84.

    Article  CAS  PubMed  Google Scholar 

  17. Geng Y, Savage SM, Razani-Boroujerdi S, Sopori ML. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. J Immunol. 1996;156:2384–90.

    CAS  PubMed  Google Scholar 

  18. Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol. 2004;140:327–34.

    CAS  PubMed  Google Scholar 

  19. Valikhani M, Kavusi S, Chams-Davatchi C, et al. Impact of smoking on pemphigus. Int J Dermatol. 2008;47:567–70.

    Article  PubMed  Google Scholar 

  20. Iraji F, Yoosefi A. Healing effect of Pilocarpine gel 4% on skin lesions of pemphigus vulgaris. Int J Dermatol. 2006;45:743–6.

    Article  CAS  PubMed  Google Scholar 

  21. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol. 1990;29:363–7.

    Article  CAS  PubMed  Google Scholar 

  22. Mentink LF, Mackenzie MW, Toth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 2006;142:570–6.

    Article  CAS  PubMed  Google Scholar 

  23. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–8.

    Article  PubMed  Google Scholar 

  24. Frew JW, Martin LK, Murrell DF. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin. 2011;29:599–606.

    Article  CAS  PubMed  Google Scholar 

  25. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515–26.

    Article  Google Scholar 

  26. Guslandi M. Steroid ulcers: any news? World J Gastrointest Pharmacol Ther. 2013;4:39–40.

    PubMed Central  PubMed  Google Scholar 

  27. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622–8.

    Article  PubMed  Google Scholar 

  28. Chams‐Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27:1285–92.

    PubMed  Google Scholar 

  29. Rose E, Wever S, Zillikens D, Linse R, Haustein U, Bröcker E. Intravenous dexamethasone‐cyclophosphamide pulse therapy in comparison with oral methylprednisolone‐azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges J Dtsc Dermatol Ges. 2005;3:200–6.

    Article  Google Scholar 

  30. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447–54.

    Article  CAS  PubMed  Google Scholar 

  31. Dastgheib L, Sadati MS, Baghernejhad M. Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: A randomized controlled trial. J Dermatolog Treat. 2015;26(1):90–3.

    Google Scholar 

  32. Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis. Am J Clin Dermatol. 2014;15:503–15.

    Article  PubMed  Google Scholar 

  33. Meggitt S, Anstey A, Mohd Mustapa M, Reynolds N, Wakelin S. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711–34.

    Article  CAS  PubMed  Google Scholar 

  34. Badalamenti S, Kerdel F. Azathioprine. Comprehensive dermatologic drug therapy. Wolverton SE, editor. Philadelphia: WB Saunders Co; 2001. p. 165–79.

    Google Scholar 

  35. Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A. Treatment of oral pemphigus vulgaris. Int J Dermatol. 1994;33:803–7.

    Article  CAS  PubMed  Google Scholar 

  36. Sharma V, Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol. 2013;38:659–64.

    Article  CAS  PubMed  Google Scholar 

  37. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1065–9.

    Article  CAS  PubMed  Google Scholar 

  38. Ioannides D, Chrysomallis F, Bystryn J. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol. 2000;136:868–72.

    CAS  PubMed  Google Scholar 

  39. Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  40. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60:595–603.

    Article  PubMed  Google Scholar 

  41. Mydlarski P, Mittmann N, Shear N. Intravenous immunoglobulin: use in dermatology. Skin Therapy Lett. 2004;9:1–6.

    CAS  PubMed  Google Scholar 

  42. Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg. 2006;10:205–21.

    Article  PubMed  Google Scholar 

  43. Baum S, Greenberger S, Samuelov L, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22:83–7.

    CAS  PubMed  Google Scholar 

  44. Gürcan H, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161:723–31.

    Article  PubMed  Google Scholar 

  45. Smith TJ, Bystryn J. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135:1275–6.

    Article  CAS  PubMed  Google Scholar 

  46. Tran K, Wolverton J, Soter N. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169:916–21.

    Article  CAS  PubMed  Google Scholar 

  47. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041–8.

    Article  CAS  PubMed  Google Scholar 

  48. Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid‐sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. 2012;26:855–60.

    Article  CAS  PubMed  Google Scholar 

  49. Guillaume J, Roujeau J, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol. 1988;124:1659–63.

    Article  CAS  PubMed  Google Scholar 

  50. Kolesnik M, Becker E, Reinhold D, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28:771–80.

    Article  CAS  PubMed  Google Scholar 

  51. Mlynek A, Meurer M. Immunoadsorption in the treatment of pemphigus. Atheroscler Suppl. 2009;10:107–9.

    Article  CAS  PubMed  Google Scholar 

  52. Pfutze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology. 2009;218:237–45.

    Article  PubMed  Google Scholar 

  53. Günther C, Laske J, Frind A, Julius U, Pfeiffer C. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb™ adsorber. J Dtsch Dermatol Ges J Dtsch Dermatol Ges. 2008;6:661–3.

    Article  PubMed  Google Scholar 

  54. Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166:154–60.

    Article  CAS  PubMed  Google Scholar 

  55. Behzad M, Möbs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult‐to‐treat pemphigus vulgaris. Br J Dermatol. 2012;166:844–52.

    Article  CAS  PubMed  Google Scholar 

  56. Kaiser J, Kaatz M, Elsner P, Ziemer M. Complete remission of drug‐resistant Pemphigus vegetans treated by extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2007;21:843–4.

    Article  CAS  PubMed  Google Scholar 

  57. Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology. 1999;198:140–4.

    Article  CAS  PubMed  Google Scholar 

  58. Gollnick HP, Owsianowski M, Taube KM, Orfanos CE. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol. 1993;28:122–4.

    Article  CAS  PubMed  Google Scholar 

  59. Rook AH, Jegasothy BV, Heald P, et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med. 1990;112:303–5.

    Article  CAS  PubMed  Google Scholar 

  60. Kim J, Kim Y, Kim M, Kim S. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165:646–51.

    Article  CAS  PubMed  Google Scholar 

  61. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009;1173:683–91.

    Article  CAS  PubMed  Google Scholar 

  62. Joly P, Mouquet H, Roujeau J, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52.

    Article  CAS  PubMed  Google Scholar 

  63. Kamran B, Maryam D, Somayeh K, Mostafa M, Mahsa H, Cheyda C. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52:862–7.

    Article  CAS  PubMed  Google Scholar 

  64. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.

    Article  CAS  PubMed  Google Scholar 

  65. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis Rheum. 2006;54:2793–806.

    Article  CAS  PubMed  Google Scholar 

  66. Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150:703–8.

    Article  CAS  PubMed  Google Scholar 

  67. Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68:404–11.

    Article  CAS  PubMed  Google Scholar 

  68. Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617–22.

    Article  CAS  PubMed  Google Scholar 

  70. Kanwar AJ, Vinay K, Sawatkar G, et al. Clinical and immunological outcomes of high‐and low‐dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer‐blinded study. Br J Dermatol. 2014;170:1341–9.

    Article  CAS  PubMed  Google Scholar 

  71. Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, et al. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol. 2015;151(2):200–3.

    Article  PubMed  Google Scholar 

  72. Cho Y, Lee F, Chu C, Wang L. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol. 2014;94:472–3.

    Article  PubMed  Google Scholar 

  73. Ellebrecht CT, Choi EJ, Allman DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150:1331–5.

    Article  PubMed  Google Scholar 

  74. Ragab N, Abdallah M, El-Gohary E, Elewa R. Stress and serum TNF-alpha levels may predict disease outcome in patients with pemphigus: a preliminary study. Cutis. 2011;87:189–94.

    PubMed  Google Scholar 

  75. Feliciani C, Toto P, Wang B, Sauder DN, Amerio P, Tulli A. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol. 2003;12:466–71.

    Article  CAS  PubMed  Google Scholar 

  76. Fiorentino DF, Garcia MS, Rehmus W, Kimball AB. A pilot study of etanercept treatment for pemphigus vulgaris. Arch Dermatol. 2011;147:117–8.

    Article  PubMed  Google Scholar 

  77. Hall R, Fairley J, Woodley D, et al. A multi‐centered randomized trial of the treatment of pemphigus vulgaris patients with infliximab and prednisone compared to prednisone alone. Br J Dermatol. 2015;172(3):760–8.

    Article  CAS  PubMed  Google Scholar 

  78. El‐Darouti M, Marzouk S, Abdel Hay R, et al. The use of sulfasalazine and pentoxifylline (low‐cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol. 2009;161:313–9.

    Article  PubMed  Google Scholar 

  79. Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol. 2011;64:490–4.

    Article  PubMed  Google Scholar 

  80. Daniel BS, Murrell DF. Management of pemphigus. F1000Prime Rep. 2014;6:32.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Prajapati V, et al. Advances in pemphigus therapy. Skin Therapy Lett. 2008;13:4–7.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, University of Calgary, Calgary, AB, Canada

    Ilya Shoimer MD & Russell X. Wong MD

  2. Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada

    P. Régine Mydlarski MD, FRCPC, DABD

  3. Richmond Road Diagnostic and Treatment Centres, 1820 Richmond Road SW, Calgary, AB, T2T 5C7, Canada

    P. Régine Mydlarski MD, FRCPC, DABD

Authors
  1. Ilya Shoimer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell X. Wong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Régine Mydlarski MD, FRCPC, DABD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Régine Mydlarski MD, FRCPC, DABD .

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Alabama at Birmingham, BIRMINGHAM, Alabama, USA

    Naveed Sami

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Shoimer, I., Wong, R.X., Mydlarski, P.R. (2016). Pemphigus Vulgaris. In: Sami, N. (eds) Autoimmune Bullous Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26728-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26728-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26726-5

  • Online ISBN: 978-3-319-26728-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation